Xencor vs Zymeworks
XNCR and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How XNCR and ZYME compare
Xencor is the larger company, worth 1.4 times as much as Zymeworks ($2.6B against $1.8B).
Xencor grew revenue faster over the last twelve months (−28.6% versus −69.8% for Zymeworks).
Xencor keeps more of each dollar of sales as profit, with a net margin of −156% compared with −404% at Zymeworks.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | XNCR | ZYME |
|---|---|---|
| Size and price | ||
| Market cap | $2.6B | $1.8B |
| Share price | $34.50 | $25.84 |
| Change, 1 year | 131% | 39.5% |
| Change, 5 years | −2.7% | 32.5% |
| Beta (5Y) | −0.05 | 0.31 |
| Employees | 260 | 264 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 24.4× (better) | 49.4× |
| P/B | 5.1× (better) | 22.8× |
| FCF yield | −8.1% | −6.6% (better) |
| Fair value | $11.73 | $3.37 |
| Margin of safety | −194% (better) | −667% |
| Growth | ||
| Revenue growth (TTM) | −28.6% (better) | −69.8% |
| Revenue growth, 5Y average | 0.47% | 22.2% (better) |
| Profitability | ||
| Operating margin | −206% (better) | −419% |
| Net margin | −156% (better) | −404% |
| FCF margin | −198% (better) | −325% |
| Return on equity | −29.1% (better) | −72.3% |
| Return on invested capital | −26.6% (better) | −179% |
| Financial health | ||
| Debt / equity | 0.21 (better) | 0.00 |
| Interest coverage | −8.0× | – |
| Current ratio | 6.39 (better) | 6.32 |
| Altman Z-score | 5.01 (better) | −1.10 |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 9.3% |
| Shareholder yield | 0.00% | 9.3% (better) |
| Ownership | ||
| Held by institutions | 113% | 98.1% |
| Held by insiders | 1.6% | 58.9% |
| Insider net buying, 12 months | −$7.5M | −$6.1M (better) |
| Short interest, % of float | 17.6% | 20.3% |
Go deeper
- XNCR stock overview
- XNCR income statement
- XNCR valuation and score
- ZYME stock overview
- ZYME income statement
- ZYME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.